Encoded design integrated synthesis of nucleic acids, and phospholipids, and related pharmaceutical products

A system comprising a first compound comprising a first polycyclic aromatic ring structure and a second compound comprising a second polycyclic aromatic ring structure, wherein the π structures of the first and second polycyclic aromatic rings interact to form a heterodimer,

• wherein the interaction between the π structures can have at least two different orientations of the heterodimer,
• wherein the first compound has the structure:
• wherein the dotted circles independently indicate optional aromaticity,
• m and n are independently 0 or 1,
• R3C, R6C, R9C, and R12C are independently hydrogen, halogen, hydroxylalkyl optionally substituted with hydroxy or —COOH, hydroxylalkoxy optionally substituted with hydroxy or —COOH, hydroxylpolyethyleneoxy, —OCH2COOH, —OCOCH2OH, —O(CH2)1-6O(P(O)(OH))O)0-6(CH2)1-6OR, and at least three of R3C, R6C, R9C, and R12C is not hydrogen, and
• R is independently at each occurrence hydrogen, alkyl, or acyl;
• or
• salts thereof;
• and
• the second compound has the structure:
• wherein R3S, R6S, R9S, and R12S are independently hydroxylalkyl optionally substituted with hydroxy or —COOH, hydroxylalkoxy optionally substituted with hydroxy or —COOH, hydroxylpolyethyleneoxy, oxalate (—OC(O)C(O)OH), —OCOCH2OH, or —O(CHD)1-6(OP(O)(OH))0-3O(CH2)1-6OR, and
• R is independently at each occurrence hydrogen, alkyl, or acyl;
• or
• salts thereof.